Revenue was $115.8 million for the second quarter, representing a 170% increase over the corresponding period of 2020 and a 9% increase compared to the first quarter of 2021.

Launched Chromium X, a next-generation instrument and platform for single cell analysis enabling million cell experiments and accelerating discoveries.

Began shipping Visium Spatial Gene Expression for FFPE, a new assay that gives researchers access to whole transcriptome spatial profiling of preserved tissue blocks.

Entered into a global settlement and cross-license agreement with Bio-Rad Laboratories, Inc. resolving all outstanding litigation.